中华小儿外科杂志
中華小兒外科雜誌
중화소인외과잡지
CHINESE JOURNAL OF PEDIATRIC SURGERY
2014年
2期
89-92
,共4页
植勇%廖凯男%熊耕%彭强%刘铭
植勇%廖凱男%熊耕%彭彊%劉銘
식용%료개남%웅경%팽강%류명
血管瘤%普萘洛尔%小鼠,裸
血管瘤%普萘洛爾%小鼠,裸
혈관류%보내락이%소서,라
Hemangioma%Propranolol%Mice,nude
目的 探讨普萘洛尔对增殖期血管瘤的治疗作用及其机制.方法 将手术切除的婴幼儿增殖期血管瘤新鲜组织块移植于裸鼠皮下,建立血管瘤动物模型；在移植后的第45天,将移植瘤组织均成活的40只实验裸鼠随机分为2组:普萘洛尔治疗组和生理盐水对照组,每组20只,分别灌注普萘洛尔溶液和生理盐水治疗.每7d观察一次移植瘤的生长情况和测量肿瘤体积.在首次药物干预后的第7、14、21、28天,每组分别随机处死5只裸鼠,切取移植的瘤体组织各10个.病理组织切片观测肿瘤的病理组织学改变；免疫组化法检测移植瘤组织中血管内皮祖细胞标志物CD133及细胞增殖核抗原Ki-67的表达情况；PCR检测瘤体组织中CD133和CD31表达水平.结果 药物干预后14d开始,普萘洛尔组瘤体体积小于生理盐水组(70.6±4.5比93.4±6.3)mm3 (P＜0.05).免疫组化检测第28天时普萘洛尔组瘤体的CD133和Ki-67阳性细胞百分率明显低于第七天时(35.6±1.8比65.4±4.5;8.8±0.7比45.4±6.1)(P＜0.01).PCR检测普萘洛尔组的CD133水平逐渐降低,CD31水平逐渐升高(0.59±0.05,0.20±0.02；0.30±0.03,1.25±0.02).而生理盐水组免疫组化CD133、Ki-67阳性细胞百分率(65.4±5.1,45.4±6.4)及CD133、CD31PCR检测值(0.59±0.05,0.30±0.03)均无明显改变(P＞0.05).结论 本实验显示普萘洛尔对血管瘤移植模型中的增殖期血管瘤有一定的治疗作用.其早期细胞机制与促进瘤体中内皮祖细胞向成熟内皮细胞转化有关.
目的 探討普萘洛爾對增殖期血管瘤的治療作用及其機製.方法 將手術切除的嬰幼兒增殖期血管瘤新鮮組織塊移植于裸鼠皮下,建立血管瘤動物模型；在移植後的第45天,將移植瘤組織均成活的40隻實驗裸鼠隨機分為2組:普萘洛爾治療組和生理鹽水對照組,每組20隻,分彆灌註普萘洛爾溶液和生理鹽水治療.每7d觀察一次移植瘤的生長情況和測量腫瘤體積.在首次藥物榦預後的第7、14、21、28天,每組分彆隨機處死5隻裸鼠,切取移植的瘤體組織各10箇.病理組織切片觀測腫瘤的病理組織學改變；免疫組化法檢測移植瘤組織中血管內皮祖細胞標誌物CD133及細胞增殖覈抗原Ki-67的錶達情況；PCR檢測瘤體組織中CD133和CD31錶達水平.結果 藥物榦預後14d開始,普萘洛爾組瘤體體積小于生理鹽水組(70.6±4.5比93.4±6.3)mm3 (P＜0.05).免疫組化檢測第28天時普萘洛爾組瘤體的CD133和Ki-67暘性細胞百分率明顯低于第七天時(35.6±1.8比65.4±4.5;8.8±0.7比45.4±6.1)(P＜0.01).PCR檢測普萘洛爾組的CD133水平逐漸降低,CD31水平逐漸升高(0.59±0.05,0.20±0.02；0.30±0.03,1.25±0.02).而生理鹽水組免疫組化CD133、Ki-67暘性細胞百分率(65.4±5.1,45.4±6.4)及CD133、CD31PCR檢測值(0.59±0.05,0.30±0.03)均無明顯改變(P＞0.05).結論 本實驗顯示普萘洛爾對血管瘤移植模型中的增殖期血管瘤有一定的治療作用.其早期細胞機製與促進瘤體中內皮祖細胞嚮成熟內皮細胞轉化有關.
목적 탐토보내락이대증식기혈관류적치료작용급기궤제.방법 장수술절제적영유인증식기혈관류신선조직괴이식우라서피하,건립혈관류동물모형；재이식후적제45천,장이식류조직균성활적40지실험라서수궤분위2조:보내락이치료조화생리염수대조조,매조20지,분별관주보내락이용액화생리염수치료.매7d관찰일차이식류적생장정황화측량종류체적.재수차약물간예후적제7、14、21、28천,매조분별수궤처사5지라서,절취이식적류체조직각10개.병리조직절편관측종류적병리조직학개변；면역조화법검측이식류조직중혈관내피조세포표지물CD133급세포증식핵항원Ki-67적표체정황；PCR검측류체조직중CD133화CD31표체수평.결과 약물간예후14d개시,보내락이조류체체적소우생리염수조(70.6±4.5비93.4±6.3)mm3 (P＜0.05).면역조화검측제28천시보내락이조류체적CD133화Ki-67양성세포백분솔명현저우제칠천시(35.6±1.8비65.4±4.5;8.8±0.7비45.4±6.1)(P＜0.01).PCR검측보내락이조적CD133수평축점강저,CD31수평축점승고(0.59±0.05,0.20±0.02；0.30±0.03,1.25±0.02).이생리염수조면역조화CD133、Ki-67양성세포백분솔(65.4±5.1,45.4±6.4)급CD133、CD31PCR검측치(0.59±0.05,0.30±0.03)균무명현개변(P＞0.05).결론 본실험현시보내락이대혈관류이식모형중적증식기혈관류유일정적치료작용.기조기세포궤제여촉진류체중내피조세포향성숙내피세포전화유관.
Objective To explore the therapeutic effects and cellular mechanism of propranolol in the treatment of proliferating hemangioma.Methods Hemangioma model in nude mice was established through fresh hemangioma tissue transplantation.A total of 40 hemangioma mice were divided randomly into propranolol and physiological saline groups.The animals received propranolol and physiological saline treatment separately.Five mice in each group were sacrificed randomly every 7 days.Tumor volume was measured.CD133 and Ki-67 in cells were tested by immunohistochemistry.And CD133 and CD31 in tumor were detected by reverse transcription-polymerase chain reaction (RTPCR).Results After 14 days,tumor volume in propranolol group was significantly smaller than that in physiological saline group (70.6 ± 4.5 vs.93.4± 6.3) mm3 (P＜0.05).In propranolol group,the CD133 and Ki-67 positive cell rate of tumor at Day 28 were significantly lower than that at Day 7(35.6 ± 1.8 vs 65.4 ± 4.5;8.8 ± 0.7 vs 45.4 ± 6.1) (P＜0.01).In propranolol group,the expression of CD133 declined while the expression of CD31 increased at Day 28 (0.59 ± 0.05,0.20 ± 0.02; 0.30 ± 0.03,1.25 ± 0.02).In physiological saline group,both the positive cell rate of CD133,Ki-67 (65.4 ± 5.1,45.4 ± 6.4)and the expression of CD133 and CD31 (0.59 ± 0.05,0.30 ± 0.03)showed insignificant changes at different timepoints (P＞0.05).Conclusions Propranolol has significant therapeutic effects on proliferating hemangioma in nude mice.And the mechanism during prophase is associated with mature endothelial cells derived from vascular endothelial progenitor cells.
